This site is intended only for healthcare professionals in Hong Kong SAR.
Click here for CIBINQO Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
An appropriate CIBINQO patient should meet all of the following:
• Platelets ≥150 × 103/mm3
• Absolute lymphocyte count (ALC) ≥0.5 × 103/mm3
• Absolute neutrophil count (ANC) ≥1.2 × 103/mm3
• Haemoglobin (Hb) ≥10 g/dL
Consistent safety profile with >3100 patients studied across JADE clinical trials1–7
Ready to get a patient started?
The CIBINQO Prescriber Guide can help.
Patient safety is of paramount importance throughout the life cycle of a medicine - and pharmaceutical companies have ethical and regulatory responsibilities to monitor the safety of the products they sell for as long as they are used by consumers anywhere in the world. The Drug Safety Unit at Pfizer Corporation Hong Kong Limited. address product experience reports including adverse events. If you have any experience pertinent to the above, please contact us at (852) 2811 9711 as soon as possible.
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in to Hong Kong. If you are a member of the public wishing to access information on a specific medicine, please visit www.pfizer.com.hk
The information provided in this site is intended only for Health Professionals who reside in Hong Kong, and the products discussed herein may have different product labeling in different countries/regions. The site is for information purpose only, and nothing herein shall be construed as providing any kind of medical advice or recommendation or product promotion. Pfizer Corporation Hong Kong Limited is a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.
Copyright© 2023 Pfizer Corporation Hong Kong Limited. All rights reserved.
PP-UNP-HKG-0116 MAY 2023